trilaciclib + docetaxel

**Trilaciclib + docetaxel** is an investigational combination therapy currently being evaluated in clinical trials for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior line of therapy. Trilaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor administered intravenously before docetaxel chemotherapy. Its primary purpose in this combination is to protect bone marrow from chemotherapy-induced myelosuppression by transiently arresting hematopoietic stem and progenitor cells in the G1 phase, thereby reducing the incidence and severity of toxicities like neutropenia and febrile neutropenia. Docetaxel is a taxane-class chemotherapeutic agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The combination is being investigated in phase II studies for its efficacy in reducing hematologic toxicity and improving outcomes in NSCLC[1][3][5].

Brand names

CoselaTaxotere

Other names

trilaciclib + docetaxel